Ionis Pharmaceuticals (IONS) reaffirms guidance
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Join SI Premium – FREE
Ionis Pharmaceuticals (NASDAQ: IONS) is reaffirming its previously announced financial guidance for the fiscal year ending December 31, 2026, which remains unchanged from the financial guidance the Company provided on April 29, 2026 in its first quarter 2026 earnings release.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- T-Mobile (TMUS) Tops Q2 EPS by 27c; offers outlook
- MarineMax (HZO) Misses Q3 EPS by 2c; offers guidance
- Gentherm (THRM) Tops Q2 EPS by 19c ; Offers Guidance
Create E-mail Alert Related Categories
Corporate News, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
